StemCells, Inc.
StemCells, Inc. Initiates Landmark Trial Targeting "Communication Highway" of the Brain
Published in Physician Law Weekly, December 9th, 2009
StemCells, Inc. (NASDAQ: STEM) announced that it has commenced patient recruitment for a Phase I clinical trial designed to test the safety and preliminary efficacy of its HuCNS-SC® purified human neural stem cells in Pelizaeus-Merzbacher Disease (PMD), a neurological disorder that primarily afflicts children. The study is being conducted at the University of California, San Francisco (UCSF) Children's Hospital, one of the leading medical centers in the United States for neonatology, pediatric neurology and neurosurgery.
PMD results from a defective gene and is characterized by a lack of myelin, a substance that surrounds and insulates nerve cells' communications...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
Source: Physician Law Weekly (2009-12-09)
More Articles from Physician Law Weekly
- A.P. Pharma, Inc.
A.P. Pharma Receives Notice of Compliance with Nasdaq Continued Listing Requirements - Aafprs
AAFPRS Opposes the Proposed Tax on Medical Procedures - Alcohol and Alcoholism
Findings from University of Gothenburg, Sahlgrenska Academy broaden understanding of alcohol and alcoholism - Alliance HealthCare Services, Inc.
Alliance HealthCare Services Announces Pricing of Private Offering of $190 Million of Senior Notes and Receipt of Commitments for $460 Million Senior Secured Term Loan and $120 Million Revolving Credit Facility - Alternatives to Laboratory Animals
New alternatives to laboratory animals study results from J. Bailey et al described - American Academy of Actuaries
Actuaries to Senate: Strengthen Individual Mandate - More from this issue of Physician Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
